Earlier this week, Cytonics CEO Joey Bose sat down with Kevin O’Leary* — the outspoken investor and Shark Tank personality known for cutting through hype and getting straight to the point.
The topic?
How a small biotech company is doing what Big Pharma hasn’t: engineering a drug to actually stop osteoarthritis — and funding it through everyday investors, not institutions.
“What he’s talking about is the future of medicine… not just treating symptoms, but providing something meaningful. A true cure.” — Kevin O’Leary
Kevin asked the right questions.
Joey answered with the facts:
- 10,000+ patients already treated with our first-gen therapy (APIC)
- CYT-108 — a recombinant, lab-optimized version — has completed Phase 1 clinical trials
- 25 issued patents protecting all core technologies and establishing CYT-108 as a potential platform technology
- $15M+ raised from over 6,000 investors through Equity Crowdfunding…
- …and zero venture capital in the cap table!
“We’re not a startup. We’re an upstart — a challenge to Big Pharma and how drug development has traditionally been financed.” — Joey Bose
This wasn’t just a PR exercise.
It was a moment of clarity.
When a mainstream investor recognizes the scientific and strategic depth of what we’re building — without VC funding, without pharma partnerships — that says something.
“This is a massive market. If this works, it saves a lot of money and a lot of pain. That’s a powerful combination for an investor.” — Kevin O’Leary
We’re not here to sell sizzle. We’re here to fix a problem 500 million people live with every day.
And we’re building this drug the same way we built this company: from the ground up, with people who believe in real science and real ownership.
👉 Watch the full interview with Kevin O’Leary on YouTube
Appreciatively,
Joey Bose
President & CEO
Reg A Disclaimer
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
*Kevin O’Leary is a paid spokesperson for StartEngine. See his 17(b) disclosure, here.
